Studies have shown that blockade of ICC development in BALB/c mice by the anti-ckit monoclonal antibody ACK2 leads to severe abnormalities in intestinal motility, reduces the number of ICC in the small intestine, and inhibits ICC proliferation and development (Torihashi et al., 1995; Streutker et al., 2007). This evidence concerns the gene KIT and intrahepatic cholangiocarcinoma.